Closed-Loop Stimulation in the Control of Focal Epilepsy

Joseph R. Smith, Kostas Fountas, Anthony M Murro, Yong D Park, Patrick D. Jenkins, David A. Greene, Rosana Esteller

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

This chapter describes the results of a multicenter study of a closed-loop neurostimulation system called the responsive neurostimulator (RNS) system undertaken by the NeuroPace, Inc. The institution performed nine implants and all cases involved more than one year follow-up. One of these nine (the only case without preoperative invasive monitoring) cases was an insulin dependent juvenile diabetic who was subsequently found to have anti-GAD antibody. This patient never responded to the neurostimulator system and her initial IPG was not replaced when the battery depleted. Follow-up on the other eight cases ranged from 19 to 32 months. All of these eight cases underwent preimplant invasive monitoring with discrete seizure focus localization. The median seizure frequency reduction was 56% and the mean reduction was 65%. The range in seizure frequency reduction was 43-100%. Seven cases required replacement of IPGs due to battery depletion and the time to IPG replacement ranged from 12 to 26 months with a median of 22 months and a mean of 21 months. There has been only one infection requiring explantation of the system. This infection occurred 16 months after implantation of a new IPG and 28 months after the original implantation. No adverse neurological events were reported in these cases. Observation of this study also support the ability of this automated seizure detection/therapeutic stimulation device to positively influence electrographic seizure activity. However, the study is still in a preliminary phase and more data is required to define optimal stimulation parameters as well as patient candidacy for seizure control.

Original languageEnglish (US)
Title of host publicationNeuromodulation
PublisherElsevier Ltd.
Pages657-662
Number of pages6
Volume2
ISBN (Print)9780123742483
DOIs
StatePublished - Dec 1 2009

Fingerprint

Partial Epilepsy
Seizures
Infection
Multicenter Studies
Anti-Idiotypic Antibodies
Observation
Insulin
Equipment and Supplies

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Smith, J. R., Fountas, K., Murro, A. M., Park, Y. D., Jenkins, P. D., Greene, D. A., & Esteller, R. (2009). Closed-Loop Stimulation in the Control of Focal Epilepsy. In Neuromodulation (Vol. 2, pp. 657-662). Elsevier Ltd.. https://doi.org/10.1016/B978-0-12-374248-3.00054-9

Closed-Loop Stimulation in the Control of Focal Epilepsy. / Smith, Joseph R.; Fountas, Kostas; Murro, Anthony M; Park, Yong D; Jenkins, Patrick D.; Greene, David A.; Esteller, Rosana.

Neuromodulation. Vol. 2 Elsevier Ltd., 2009. p. 657-662.

Research output: Chapter in Book/Report/Conference proceedingChapter

Smith, JR, Fountas, K, Murro, AM, Park, YD, Jenkins, PD, Greene, DA & Esteller, R 2009, Closed-Loop Stimulation in the Control of Focal Epilepsy. in Neuromodulation. vol. 2, Elsevier Ltd., pp. 657-662. https://doi.org/10.1016/B978-0-12-374248-3.00054-9
Smith JR, Fountas K, Murro AM, Park YD, Jenkins PD, Greene DA et al. Closed-Loop Stimulation in the Control of Focal Epilepsy. In Neuromodulation. Vol. 2. Elsevier Ltd. 2009. p. 657-662 https://doi.org/10.1016/B978-0-12-374248-3.00054-9
Smith, Joseph R. ; Fountas, Kostas ; Murro, Anthony M ; Park, Yong D ; Jenkins, Patrick D. ; Greene, David A. ; Esteller, Rosana. / Closed-Loop Stimulation in the Control of Focal Epilepsy. Neuromodulation. Vol. 2 Elsevier Ltd., 2009. pp. 657-662
@inbook{b8aee23bd17844db9ed72679ed69ec6d,
title = "Closed-Loop Stimulation in the Control of Focal Epilepsy",
abstract = "This chapter describes the results of a multicenter study of a closed-loop neurostimulation system called the responsive neurostimulator (RNS) system undertaken by the NeuroPace, Inc. The institution performed nine implants and all cases involved more than one year follow-up. One of these nine (the only case without preoperative invasive monitoring) cases was an insulin dependent juvenile diabetic who was subsequently found to have anti-GAD antibody. This patient never responded to the neurostimulator system and her initial IPG was not replaced when the battery depleted. Follow-up on the other eight cases ranged from 19 to 32 months. All of these eight cases underwent preimplant invasive monitoring with discrete seizure focus localization. The median seizure frequency reduction was 56{\%} and the mean reduction was 65{\%}. The range in seizure frequency reduction was 43-100{\%}. Seven cases required replacement of IPGs due to battery depletion and the time to IPG replacement ranged from 12 to 26 months with a median of 22 months and a mean of 21 months. There has been only one infection requiring explantation of the system. This infection occurred 16 months after implantation of a new IPG and 28 months after the original implantation. No adverse neurological events were reported in these cases. Observation of this study also support the ability of this automated seizure detection/therapeutic stimulation device to positively influence electrographic seizure activity. However, the study is still in a preliminary phase and more data is required to define optimal stimulation parameters as well as patient candidacy for seizure control.",
author = "Smith, {Joseph R.} and Kostas Fountas and Murro, {Anthony M} and Park, {Yong D} and Jenkins, {Patrick D.} and Greene, {David A.} and Rosana Esteller",
year = "2009",
month = "12",
day = "1",
doi = "10.1016/B978-0-12-374248-3.00054-9",
language = "English (US)",
isbn = "9780123742483",
volume = "2",
pages = "657--662",
booktitle = "Neuromodulation",
publisher = "Elsevier Ltd.",

}

TY - CHAP

T1 - Closed-Loop Stimulation in the Control of Focal Epilepsy

AU - Smith, Joseph R.

AU - Fountas, Kostas

AU - Murro, Anthony M

AU - Park, Yong D

AU - Jenkins, Patrick D.

AU - Greene, David A.

AU - Esteller, Rosana

PY - 2009/12/1

Y1 - 2009/12/1

N2 - This chapter describes the results of a multicenter study of a closed-loop neurostimulation system called the responsive neurostimulator (RNS) system undertaken by the NeuroPace, Inc. The institution performed nine implants and all cases involved more than one year follow-up. One of these nine (the only case without preoperative invasive monitoring) cases was an insulin dependent juvenile diabetic who was subsequently found to have anti-GAD antibody. This patient never responded to the neurostimulator system and her initial IPG was not replaced when the battery depleted. Follow-up on the other eight cases ranged from 19 to 32 months. All of these eight cases underwent preimplant invasive monitoring with discrete seizure focus localization. The median seizure frequency reduction was 56% and the mean reduction was 65%. The range in seizure frequency reduction was 43-100%. Seven cases required replacement of IPGs due to battery depletion and the time to IPG replacement ranged from 12 to 26 months with a median of 22 months and a mean of 21 months. There has been only one infection requiring explantation of the system. This infection occurred 16 months after implantation of a new IPG and 28 months after the original implantation. No adverse neurological events were reported in these cases. Observation of this study also support the ability of this automated seizure detection/therapeutic stimulation device to positively influence electrographic seizure activity. However, the study is still in a preliminary phase and more data is required to define optimal stimulation parameters as well as patient candidacy for seizure control.

AB - This chapter describes the results of a multicenter study of a closed-loop neurostimulation system called the responsive neurostimulator (RNS) system undertaken by the NeuroPace, Inc. The institution performed nine implants and all cases involved more than one year follow-up. One of these nine (the only case without preoperative invasive monitoring) cases was an insulin dependent juvenile diabetic who was subsequently found to have anti-GAD antibody. This patient never responded to the neurostimulator system and her initial IPG was not replaced when the battery depleted. Follow-up on the other eight cases ranged from 19 to 32 months. All of these eight cases underwent preimplant invasive monitoring with discrete seizure focus localization. The median seizure frequency reduction was 56% and the mean reduction was 65%. The range in seizure frequency reduction was 43-100%. Seven cases required replacement of IPGs due to battery depletion and the time to IPG replacement ranged from 12 to 26 months with a median of 22 months and a mean of 21 months. There has been only one infection requiring explantation of the system. This infection occurred 16 months after implantation of a new IPG and 28 months after the original implantation. No adverse neurological events were reported in these cases. Observation of this study also support the ability of this automated seizure detection/therapeutic stimulation device to positively influence electrographic seizure activity. However, the study is still in a preliminary phase and more data is required to define optimal stimulation parameters as well as patient candidacy for seizure control.

UR - http://www.scopus.com/inward/record.url?scp=77956661497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956661497&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-374248-3.00054-9

DO - 10.1016/B978-0-12-374248-3.00054-9

M3 - Chapter

SN - 9780123742483

VL - 2

SP - 657

EP - 662

BT - Neuromodulation

PB - Elsevier Ltd.

ER -